Evaluation and solubility improvement of Carvedilol: PSC[n]arene inclusion complexes with acute oral toxicity studies
The aqua phobic molecules that are practically insoluble in aqueous media demonstrate a staggeringly slow intrinsic dissolution rate. In this work, we exemplify the utility of calixarenes as a tool to form inclusion complexes with Carvedilol (CDL). It is poorly water soluble drug. CDL is a Biopharma...
Gespeichert in:
Veröffentlicht in: | Journal of Inclusion Phenomena and Macrocyclic Chemistry 2012-08, Vol.73 (1-4), p.295-303 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The aqua phobic molecules that are practically insoluble in aqueous media demonstrate a staggeringly slow intrinsic dissolution rate. In this work, we exemplify the utility of calixarenes as a tool to form inclusion complexes with Carvedilol (CDL). It is poorly water soluble drug. CDL is a Biopharmaceutical Classification System (BCS) Class II drug and it is a nonselective β-adrenegenic blocking agent with α1-blocking activity. It is mainly used in the management of hypertension. The maximum complexation of the drug was accomplished after 48 h of stirring with
para
sulphonato calix[4]arene (PSC[4]arene) and
para
sulphonato calix[6]arene (PSC[6]arene) in water and evaporation of water to acquire solid complexes. The study includes characterisation of both the complexes—physical mixtures of drug and PSC[4]arene and PSC[6]arenes by different methods like Fourier-transform infra red spectroscopy, differential scanning calorimetry and powder X-ray diffraction, proton nuclear magnetic resonance. This studies shows that there is electrostatic interaction between drug and PSC[
n
]arenes. The complexation was determined by phase solubility study. The prepared complexes exhibited improved in vitro dissolution profile and decreased in vivo acute oral toxicity compared to the pure drug. |
---|---|
ISSN: | 0923-0750 1573-1111 |
DOI: | 10.1007/s10847-011-0056-x |